SG11201408491SA - Analogs of glucagon exhibiting gip receptor activity - Google Patents
Analogs of glucagon exhibiting gip receptor activityInfo
- Publication number
- SG11201408491SA SG11201408491SA SG11201408491SA SG11201408491SA SG11201408491SA SG 11201408491S A SG11201408491S A SG 11201408491SA SG 11201408491S A SG11201408491S A SG 11201408491SA SG 11201408491S A SG11201408491S A SG 11201408491SA SG 11201408491S A SG11201408491S A SG 11201408491SA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- indiana
- gip receptor
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662874P | 2012-06-21 | 2012-06-21 | |
| US201361787973P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/046229 WO2013192130A1 (en) | 2012-06-21 | 2013-06-18 | Analogs of glucagon exhibiting gip receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408491SA true SG11201408491SA (en) | 2015-01-29 |
Family
ID=48692696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408491SA SG11201408491SA (en) | 2012-06-21 | 2013-06-18 | Analogs of glucagon exhibiting gip receptor activity |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9868772B2 (enExample) |
| EP (1) | EP2864350B1 (enExample) |
| JP (1) | JP6300239B2 (enExample) |
| KR (1) | KR20150039748A (enExample) |
| CN (1) | CN104583233B (enExample) |
| AR (1) | AR091478A1 (enExample) |
| AU (1) | AU2013277372B2 (enExample) |
| BR (1) | BR112014031671A2 (enExample) |
| CA (1) | CA2877127A1 (enExample) |
| CL (1) | CL2014003421A1 (enExample) |
| CO (1) | CO7170125A2 (enExample) |
| CR (1) | CR20150015A (enExample) |
| DK (1) | DK2864350T3 (enExample) |
| EA (1) | EA029025B1 (enExample) |
| ES (1) | ES2674946T3 (enExample) |
| HR (1) | HRP20180936T1 (enExample) |
| HU (1) | HUE039267T2 (enExample) |
| IL (1) | IL236386B (enExample) |
| MX (1) | MX356000B (enExample) |
| MY (1) | MY185217A (enExample) |
| PE (1) | PE20150863A1 (enExample) |
| PH (1) | PH12014502857A1 (enExample) |
| PL (1) | PL2864350T3 (enExample) |
| PT (1) | PT2864350T (enExample) |
| RS (1) | RS57347B1 (enExample) |
| SG (1) | SG11201408491SA (enExample) |
| SI (1) | SI2864350T1 (enExample) |
| TR (1) | TR201808818T4 (enExample) |
| TW (1) | TWI644920B (enExample) |
| WO (1) | WO2013192130A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2640916T3 (es) | 2012-04-26 | 2017-11-07 | Bristol-Myers Squibb Company | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| DK3004155T3 (da) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP6581656B2 (ja) | 2014-10-24 | 2019-09-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト |
| KR102291020B1 (ko) | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| FI3322437T3 (fi) | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| AU2016379403B2 (en) | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| EP3467106B1 (en) | 2016-05-24 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Peptide compound |
| CN122440793A (zh) | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| CN115304666B (zh) * | 2017-11-24 | 2025-09-19 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| MX2020010716A (es) | 2018-04-10 | 2021-03-09 | Sanofi Aventis Deutschland | Metodo para escindir de la fase solida peptidos unidos a una fase solida. |
| SG11202010016QA (en) | 2018-04-10 | 2020-11-27 | Sanofi Aventis Deutschland | Lixisenatide synthesis with capping |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| ES3068975T3 (en) * | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| US11166910B2 (en) | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
| EP4112637A4 (en) * | 2020-02-24 | 2024-04-03 | Shenzhen Turier Biotech Co., Ltd. | POLYPEPTIDE COMPOUND AND ITS APPLICATION IN THE PREVENTION OR TREATMENT OF DIABETES OR A COMPLICATION OF DIABETES |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| CN114621327B (zh) * | 2020-12-10 | 2023-08-18 | 江苏中新医药有限公司 | GLP-1、GIP和Gcg多重受体激动蛋白质 |
| US20240059752A1 (en) | 2020-12-23 | 2024-02-22 | Zhejiang Doer Biologics Co., Ltd. | Long-acting glucagon derivative |
| US20240174728A1 (en) * | 2021-01-22 | 2024-05-30 | Shenzhen Turier Biotech Co., Ltd. | A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis |
| JP2024525843A (ja) * | 2021-07-16 | 2024-07-12 | ぺプ２タンゴ セラピューティクス インコーポレイテッド | マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
| JP7402574B1 (ja) * | 2023-03-15 | 2023-12-21 | 株式会社合同資源 | α－ヨード置換カルボン酸 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| WO1999040942A1 (en) | 1998-02-10 | 1999-08-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations with controlled release |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| WO2004033036A2 (en) | 2002-10-04 | 2004-04-22 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| CA2651283A1 (en) | 2006-05-15 | 2007-11-22 | Wisconsin Alumni Research Foundation | Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| FR2902092B1 (fr) | 2006-06-07 | 2008-09-05 | Sapelem Soc Par Actions Simpli | Appareil de manutention de charge |
| NZ578948A (en) * | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| WO2008130158A1 (en) | 2007-04-19 | 2008-10-30 | Dong-A Pharmaceutical. Co., Ltd | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| CA2728284C (en) | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY |
| WO2010148089A1 (en) * | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| ES2661228T3 (es) * | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| US8778872B2 (en) * | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| CN103857408B (zh) * | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| JP6184404B2 (ja) * | 2011-06-22 | 2017-08-23 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプターコアゴニスト |
| SI2864350T1 (en) * | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
-
2013
- 2013-06-18 SI SI201331079T patent/SI2864350T1/en unknown
- 2013-06-18 KR KR20157001447A patent/KR20150039748A/ko not_active Abandoned
- 2013-06-18 BR BR112014031671A patent/BR112014031671A2/pt not_active Application Discontinuation
- 2013-06-18 ES ES13731246.8T patent/ES2674946T3/es active Active
- 2013-06-18 US US14/408,813 patent/US9868772B2/en not_active Expired - Fee Related
- 2013-06-18 JP JP2015518506A patent/JP6300239B2/ja not_active Expired - Fee Related
- 2013-06-18 CA CA2877127A patent/CA2877127A1/en not_active Abandoned
- 2013-06-18 WO PCT/US2013/046229 patent/WO2013192130A1/en not_active Ceased
- 2013-06-18 RS RS20180728A patent/RS57347B1/sr unknown
- 2013-06-18 TW TW102121585A patent/TWI644920B/zh not_active IP Right Cessation
- 2013-06-18 DK DK13731246.8T patent/DK2864350T3/en active
- 2013-06-18 HR HRP20180936TT patent/HRP20180936T1/hr unknown
- 2013-06-18 HU HUE13731246A patent/HUE039267T2/hu unknown
- 2013-06-18 PT PT137312468T patent/PT2864350T/pt unknown
- 2013-06-18 AU AU2013277372A patent/AU2013277372B2/en not_active Ceased
- 2013-06-18 MX MX2014015556A patent/MX356000B/es active IP Right Grant
- 2013-06-18 PE PE2014002465A patent/PE20150863A1/es not_active Application Discontinuation
- 2013-06-18 SG SG11201408491SA patent/SG11201408491SA/en unknown
- 2013-06-18 TR TR2018/08818T patent/TR201808818T4/tr unknown
- 2013-06-18 MY MYPI2014003510A patent/MY185217A/en unknown
- 2013-06-18 AR ARP130102143 patent/AR091478A1/es unknown
- 2013-06-18 CN CN201380043984.5A patent/CN104583233B/zh not_active Expired - Fee Related
- 2013-06-18 EP EP13731246.8A patent/EP2864350B1/en not_active Not-in-force
- 2013-06-18 EA EA201590065A patent/EA029025B1/ru not_active IP Right Cessation
- 2013-06-18 PL PL13731246T patent/PL2864350T3/pl unknown
-
2014
- 2014-12-17 CL CL2014003421A patent/CL2014003421A1/es unknown
- 2014-12-21 IL IL236386A patent/IL236386B/en active IP Right Grant
- 2014-12-22 PH PH12014502857A patent/PH12014502857A1/en unknown
-
2015
- 2015-01-19 CR CR20150015A patent/CR20150015A/es not_active Application Discontinuation
- 2015-01-19 CO CO15009514A patent/CO7170125A2/es unknown
-
2017
- 2017-12-04 US US15/830,158 patent/US20180105569A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408536WA (en) | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201408385TA (en) | Methods of detecting diseases or conditions | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201407747QA (en) | A method and apparatus for facilitating the management of health and security | |
| SG11201407028WA (en) | St2l antagonists and methods of use | |
| SG11201407483YA (en) | Compositions and methods for modulating smn gene family expression | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201406625XA (en) | Anti-fcrn antibodies | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201408332TA (en) | Polyisobutylene composition having internal vinylidene and process for preparing the polyisobutylene polymer composition |